share_log

ParaZero Technologies | SC 13G: Statement of acquisition of beneficial ownership by individuals-Medigus Ltd.(20.04%)

SEC announcement ·  Feb 14 16:07
Summary by Moomoo AI
On December 31, 2023, Medigus Ltd., an Israeli company, filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a significant stake in ParaZero Technologies Ltd. According to the filing, Medigus Ltd. holds 2,019,153 ordinary shares of ParaZero Technologies, representing 20.04% of the company's issued and outstanding shares. The filing, made under Rule 13d-1(d), indicates that Medigus Ltd. does not seek to change or influence the control of ParaZero Technologies. The shares are held directly by Medigus Ltd., and the beneficial ownership reported reflects a passive investment position. The address of ParaZero Technologies' principal executive offices is listed as 30 Dov Hoz, Kiryat Ono, Israel, while Medigus Ltd.'s principal business office is located at 10 HaNechoshet Street, Tel Aviv, Israel. The filing was signed by Tali Dinar, Chief Financial Officer of Medigus Ltd., on February 14, 2024, certifying the accuracy of the information provided.
On December 31, 2023, Medigus Ltd., an Israeli company, filed a Schedule 13G with the United States Securities and Exchange Commission, disclosing a significant stake in ParaZero Technologies Ltd. According to the filing, Medigus Ltd. holds 2,019,153 ordinary shares of ParaZero Technologies, representing 20.04% of the company's issued and outstanding shares. The filing, made under Rule 13d-1(d), indicates that Medigus Ltd. does not seek to change or influence the control of ParaZero Technologies. The shares are held directly by Medigus Ltd., and the beneficial ownership reported reflects a passive investment position. The address of ParaZero Technologies' principal executive offices is listed as 30 Dov Hoz, Kiryat Ono, Israel, while Medigus Ltd.'s principal business office is located at 10 HaNechoshet Street, Tel Aviv, Israel. The filing was signed by Tali Dinar, Chief Financial Officer of Medigus Ltd., on February 14, 2024, certifying the accuracy of the information provided.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more